Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Portola Pharma (PTLA)

Portola Pharma (PTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,020,207
  • Shares Outstanding, K 77,819
  • Annual Sales, $ 40,130 K
  • Annual Income, $ -350,220 K
  • 60-Month Beta 2.00
  • Price/Sales 8.77
  • Price/Cash Flow N/A
  • Price/Book 4.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.89
  • Number of Estimates 3
  • High Estimate -0.83
  • Low Estimate -0.93
  • Prior Year -1.04
  • Growth Rate Est. (year over year) +14.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.01 +2.38%
on 01/27/20
25.09 -46.91%
on 12/30/19
-11.74 (-46.85%)
since 12/27/19
3-Month
13.01 +2.38%
on 01/27/20
31.25 -57.38%
on 11/06/19
-16.53 (-55.38%)
since 10/29/19
52-Week
13.01 +2.38%
on 01/27/20
37.95 -64.90%
on 04/05/19
-13.30 (-49.96%)
since 01/29/19

Most Recent Stories

More News
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Forescout Technologies, Mohawk Industries, 500.com, and Portola Pharmaceuticals and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Forescout Technologies, Inc. (NASDAQ:...

FSCT : 30.02 (+0.40%)
MHK : 136.46 (-2.51%)
WBAI : 7.09 (+2.31%)
PTLA : 13.20 (+0.69%)
PORTOLA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Portola Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Portola Pharmaceuticals, Inc. ("Portola" or the "Company")(NASDAQ:PTLA) of the March 16, 2020 deadline to seek the role...

PTLA : 13.20 (+0.69%)
PORTOLA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Portola Pharmaceuticals, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - January 28, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) ("Portola" or the...

PTLA : 13.20 (+0.69%)
PORTOLA PHARMACEUTICALS, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Portola Pharmaceuticals, Inc.

Wolf Haldenstein Adler Freeman & Herz LLP , announces the filing of a federal securities class action lawsuit in the United States District Court for the Northern District of California on behalf of purchasers...

PTLA : 13.20 (+0.69%)
PTLA LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors of its Investigation into Portola Pharmaceuticals, Inc., and Encourages Investors with Losses to Contact the Firm

Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Portola Pharmaceuticals, Inc. ("Portola" or the "Company")...

PTLA : 13.20 (+0.69%)
PORTOLA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Portola Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Portola Pharmaceuticals, Inc. ("Portola" or the "Company")(NASDAQ:PTLA) of the March 16, 2020 deadline to seek the role...

PTLA : 13.20 (+0.69%)
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Portola Pharmaceuticals, Inc.- PTLA

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) from November 5, 2019 through January...

PTLA : 13.20 (+0.69%)
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Portola Pharmaceuticals, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming March 16, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Portola Pharmaceuticals, Inc. ("Portola"...

PTLA : 13.20 (+0.69%)
SHAREHOLDER ALERT - Portola Pharmaceuticals Inc. (PTLA) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: March 16, 2020

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Portola Pharmaceuticals Inc. ("Portola" or the Company") (NASDAQ: PTLA) and...

PTLA : 13.20 (+0.69%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Portola Pharmaceuticals Inc. - PTLA

Pomerantz LLP is investigating claims on behalf of investors of Portola Pharmaceuticals, Inc. ("Portola" or the "Company") (NASDAQ: PTLA). Such investors are advised to contact Robert S. Willoughby at...

PTLA : 13.20 (+0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade PTLA with:

Business Summary

Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.

See More

Key Turning Points

2nd Resistance Point 13.74
1st Resistance Point 13.42
Last Price 13.20
1st Support Level 12.92
2nd Support Level 12.74

See More

52-Week High 37.95
Fibonacci 61.8% 28.42
Fibonacci 50% 25.48
Fibonacci 38.2% 22.54
Last Price 13.20
52-Week Low 13.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar